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PreviewsCFU-F activity and neural crest character-
istics is present in adult mouse BM.
It is notable that LepR, a hormone re-
ceptor, is a marker of MSCs and that
LepR+ cells are involved in the regene-
rative response of bone and cartilage
after injury. Thus, an attractive idea is
that the fat-cell-specific hormone Leptin
and the LepR/Jak/STAT pathway, which
is blocked in db/db mice, play crucial
roles in the biological regulation (e.g.,
maintenance, proliferation, and/or differ-
entiation) of MSCs and the regenerative
responses of bone and cartilage. Thus,
the paracrine action of Leptin released
from BM adipocytes to the LepR+ MSCs
could possibly be involved in the homeo-
stasis of MSCs and MSCs-derived cells,
which should be elucidated in future
investigations.
The study of MSCs is likely to have
both biological significance and clinical
applications. In human MSCs, enriched
expression of the low-affinity nerve
growth factor receptor (LNGFR) (known
as a neural crest marker) has been repro-114 Cell Stem Cell 15, August 7, 2014 ª2014duced by many researchers (Mabuchi
et al., 2013), but the consistency of the
marker remains a problem. The next
step should be conducting comprehen-
sive analysis using LepR in multiple spe-
cies. By refining our ability to define
MSCs in vivo, the field may then shift
directions from markers to signaling
and focus on establishing MSC biology
in the near future.
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In this issue of Cell Stem Cell, Zhu et al. (2014) demonstrate that a genetically engineered glioma model
displays a functional cellular hierarchy defined by expression of the nuclear orphan receptor Tlx. Targeting
cancer stem cells through genetic deletion of TLX promotes cancer stem cell death and differentiation and
extends survival.Cancer is a genetic disease, but it initiates
and grows within a cellular context that
reflects the organization of tumors into
aberrant organ systems. The cellular
diversity within a tumor extends to the
neoplastic compartment in which genetic
and epigenetic variation manifests in dif-
ferential proliferation, survival, and migra-
tion of cancer cells. The cancer stem cell
(CSC) hypothesis is a partial explanation
for these observations because many
cancers harbor a relatively undifferenti-
ated pool of transformed cells that self-renew and propagate the entire range of
differentiated tumor progeny. However,
establishing the presence of cellular hier-
archies within a tumor and identifying
the origin of differentiated progeny is
complicated by the dynamic nature of
cancer and an inability to trace the history
of existing cancers. One challenge has
been the identification of reliable CSC sur-
face markers because these molecules
mediate interactions between cells and
their microenvironment and may be
dynamically changed after isolation ofCSCs. Further, no tumor type is geneti-
cally uniform, so markers are unlikely to
be uniformly informative in all tumors.
Tumor models derived from patient spec-
imens (e.g., patient-derived xenografts)
contain the cellular and molecular diver-
sity of the human disease but cannot
instruct us as to the natural history of
specific cells beyond genetic lineage
analysis. Alternatively, genetically engi-
neered mouse models present a useful
tool to study the natural history of tumor
hierarchies in an immune-competent
Figure 1. The Role of the Nuclear Orphan Receptor TLX in Glioblastoma
TLX-positive glioma cells are quiescent and display the capacity for self-renewal and tumor growth. TLX
marks a subpopulation of tumor cells distinct from other putative cancer stem cell (CSC) markers—SOX2
and OLIG2—suggesting the potential for different pools of CSCs or further stages in a cellular hierarchy
with SOX2 potentially indicating a transient amplifying progenitor population.
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Previewsbackground, albeit with far less genetic
diversity than human cancers. Based on
this background, Liu and colleagues
(Zhu et al., 2014) established a mouse
model that developed high-grade brain
tumors by coexpression of PDGFB and
AKT in Nestin-positive neural stem cells
(NSCs). Their results are presented in
this issue of Cell Stem Cell. Other investi-
gators have used Nestin to mark highly
tumorigenic cells, but the marker has
not proven reliable in human tumors. In
contrast, in the current study the authors
have interrogated Tailless (Tlx; Nuclear
Receptor subfamily 2 group E, NR2E1),
a nuclear orphan receptor specifically ex-
pressed in the brain and retina, to perform
lineage tracing and targeting studies.
Previous studies by this group and
others have shown that Tlx is expressed
in NSCs (Liu et al., 2008; Shi et al., 2004)
and that forced overexpression of Tlx in
conjunction with common genetic lesions
(e.g., mutant p53) induces gliomas (Liu
et al., 2010; Park et al., 2010; Zou et al.,
2012). Building on these findings, the
authors used TLX-GFP reporter mice in
conjunction with PDGFB and AKT overex-
pression to generate gliomaswith variable
GFP expression. TLX-GFP+ cells are
largely quiescent and have increased
sphere formation and tumor propagation
potential relative to TLX-GFP cells.Notably, TLX-GFP+ cells were distinct
from cells expressing other putative CSC
markers (i.e. Sox2 and Olig2), suggesting
that tumors may contain different pools
of CSCs and/or a further hierarchy of
stem and progenitor cells (Figure 1).
Because both NSCs and oligodendroglial
progenitor cells (OPCs) have been shown
to be potential cell-of-origin for gliomas,
it is possible that tumor growth in these
genetic models may not be solely driven
by a single cell type. Lineage tracing
studies with Confetti reporter mice sug-
gested that TLX+ cells can be the cell-
of-origin of gliomas and that treatment
with the oral methylator temozolomide
promotes cell cycle entry of TLX+ cells.
These results suggest that Tlx is a poten-
tial molecular target of gliomas. Indeed,
conditional ablation of TLX in their model
slows tumor growth and inhibits CSC
self-renewal, which is associated with
induction of senescence and neurogenic
differentiation measured by DCX expres-
sion. Interestingly, we previously reported
DCX as a negative prognostic indicator for
glioblastoma in combination with other
genes (Rich et al., 2005).
To further determine potential mole-
cular mediators of Tlx, the authors per-
formed an expression analysis and
found that cell cycle regulators (includ-
ing CDKN2A, CDKN2B, and PML) andCell Stem Cell 1neuronal differentiation genes (TGFbR1
and Dlx2) were significantly upregulated
in TLX knockout CSCs. Other potential
molecules previously found to interact
with Tlx not detected in these studies
could also be relevant based on roles in
glioma CSCs, including Pten, miR-9, and
LSD1. These findings are consistent
with prior reports that Tlx functions as a
transcription repressor in controlling
CSCs. Tlx recruits histone deacetylases
(including HDAC3 and HDAC5) to its
downstream targets to repress their
transcription (Sun et al., 2007). Because
HDACs are required for the functioning
of Tlx transcriptional repressor and are
essential in the maintenance of CSCs
self-renewal, HDAC inhibitors may target
TLX+ CSCs.
The identification of novel and specific
CSC targets is potentially important
because CSCs contribute to therapeutic
resistance (Bao et al., 2006). In support
of Tlx as a CSC target, the authors per-
formed online in silico analysis using The
Cancer Genome Atlas (TCGA) bioinfor-
matics data set to show that high TLX
mRNA expression is a negative prog-
nostic factor for an unselected glioblas-
toma population (p < 0.007, Cox Propor-
tional Hazard). This observation must be
taken with caution because a further ex-
amination of the full TCGA data set with
consideration of other prognostic factors
indicates that the prognostic significance
of TLX is entirely linked to its reduced
expression in glioma CpG island methyl-
ator phenotype (G-CIMP) tumors, which
signify a genetically distinct cancer type
and are associated with IDH1 mutations
and longer survival. Excluding G-CIMP
patients, TLX expression displays no pre-
dictive value for glioblastoma patient sur-
vival (p = 0.955, Cox Proportional Hazard).
Thus, TLX is not likely a prognostic factor
itself, although the reduced TLX expres-
sion found in G-CIMPpatientsmay poten-
tially inform the biology of this distinct
population of tumors. Additionally, ge-
netic lesions (Pten, p53, etc.) potentially
interacting with Tlx may also inform its
contribution to tumor growth. While no
Tlx inhibitors have been identified, the
TLX mutant mouse is viable, albeit with
developmental abnormalities in the brain,
and Tlx has been shown to be a druggable
target (Benod et al., 2014).
The studies from Liu and colleagues
(Zhu et al., 2014) lend further support5, August 7, 2014 ª2014 Elsevier Inc. 115
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Previewsto the importance of CSCs while sup-
porting Tlx as a novel glioma CSC
marker and expanding opportunities
to investigate regulators of CSCs in a
genetic model. The combined use of
this powerful model with well character-
ized human tumor models should inform
the discovery of other CSC points of
fragility and could provide a useful tool
to detect the initial stages of brain
cancer. Although the CSC hypothesis
does not comprehensively explain all
of tumor biology, CSCs as roots of
many cancers represent an added level
of complexity in tumors, a challenge
we must face in trying to develop more
effective therapeutics.116 Cell Stem Cell 15, August 7, 2014 ª2014REFERENCES
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Somatic cells can be reprogrammed to induced pluripotent stem cells via exogenous expression of a small
set of transcription factors, but the regulatory mechanisms controlling this cell transition are poorly under-
stood. Two recent reports demonstrate the value of RNAi screens as a tool to uncover roadblocks in this
inefficient process.Groundbreaking work by Takahashi and
Yamanka has demonstrated that applying
a defined set of transcription factors
(Oct4, Sox2, Klf4, and c-Myc; OSKM)
can result in the conversion of somatic
cells into induced pluripotent stem cells
(iPSCs) (Takahashi and Yamanaka,
2006). This method has shown its robust-
ness and reproducibility—it has been
applied to a wide variety of species and
cell types including human cells (reviewed
in Theunissen and Jaenisch, 2014). It is
not surprising that since its discovery the
processes involved in the generation
of iPSCs have been studied intensively.
However, in comparison to somatic cell
nuclear transfer, direct reprogramming is
still a slow and inefficient process, indi-cating that cellular barriers are hampering
the conversion of a committed and
specialized cell into an immature and
pluripotent iPSC. Different studies in
mouse and human reprogramming have
highlighted a key role of the epigenetic
state in regulating reprogramming. How-
ever, other pathways, including TGF-b or
p53 signaling, have also been implicated
in hampering the generation of iPSCs
(reviewed in Theunissen and Jaenisch,
2014), indicating that several different
cellular processes can influence the
speed and efficiency of iPSC generation.
The identification of additional pathways
involved in reprogramming would no
doubt further enhance our understanding
of underlying mechanisms guiding re-programming. In recent issues of Cell
and Cell Reports, the groups of Ram-
alho-Santos and Rana report genome-
wide RNAi screens to delineate new
factors that affect reprogramming effi-
ciency and kinetics using human and
mouse fibroblasts, respectively, as the
starting cell types (Qin et al., 2014, Yang
et al., 2014).
Qin et al. applied the RNAi screen em-
ploying an ultracomplex library of shRNAs
in combination with next generation
sequencing (NGS) to identify roadblocks
to human cellular reprogramming. They
used a lentiviral library encompassing
600,000 shRNAs targeting almost 20,000
genes and transduced these together
with the OSKM factors and p53 RNAi
